Recent reports that co-infection with GB virus C (GBV-C) is associated with a reduced mortality in HIV-infected individuals, a slower progression to AIDS, and lower HIV viral loads, suggest a potential role of GBV-C as therapy for HIV infection. Although not known to cause any human disease, GBV-C was only recently discovered and prospective studies assessing long-term consequences of infection have not been completed. Our understanding of the host-viral interactions between humans and GBV-C is in its infancy. Further research into the intriguing relationship between GBV-C and HIV is needed before intentional inoculation of GBV-C into individuals infected with HIV should proceed. This essay explores the history of the once-popular treatment of paretic tertiary syphilis with the blood-borne pathogen Plasmodium vivax, providing a historical perspective on the current state of affairs between GBV-C and HIV. A brief review of GBV-C biology and human infection is followed by a discussion of the current challenges facing the use of this organism to treat HIV.
References
1.
HeringlakeS., OckengaJ., TillmannH.L., TrautweinC., MeissnerD., StollM., HuntJ., JouC., SolomonN., SchmidtR.E., & MannsM.P.GB virus C/hepatitis G virus infection: a favorable prognostic factor in human immunodeficiency virus-infected patients. Journal of Infectious Diseases1998; 177: 1723–1726.
2.
ToyodaH., FukudaY., HayakawaT., TakamatsuJ., & SaitoH.Effect of GB virus C/hepatitis G virus coinfection on the course of HIV infection in hemophilia patients in Japan. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1998; 17: 209–213.
3.
LefrereJ.J., Roudot-ThoravalF., Morand-JoubertL., PetitJ.C., LerableJ., ThauvinM., & MariottiM.Carriage of GB virus C/hepatitis G virus RNA is associated with a slower immunologic, virologic, and clinical progression of human immunodeficiency virus disease in coinfected persons. Journal of Infectious Diseases1999; 179: 783–789.
4.
YeoA.E., MatsumotoA., HisadaM., ShihJ.W., AlterH.J., & GoedertJ.J.Effect of hepatitis G virus infection on progression of HIV infection in patients with hemophilia. Multicenter Hemophilia Cohort Study. Annals of Internal Medicine2000; 132: 959–963.
5.
XiangJ., WunschmannS., DiekemaD.J., KlinzmanD., PatrickK.D., GeorgeS.L., & StapletonJ.T.Effect of coinfection with GB virus C on survival among patients with HIV infection. New England Journal of Medicine2001; 345: 707–714.
6.
TillmannH.L., HeikenH., Knapik-BotorA., HeringlakeS., OckengaJ., WilberJ.C., GoergenB., DetmerJ., McMorrowM., StollM., SchmidtR.E., & MannsM.P.Infection with GB virus C and reduced mortality among HIV-infected patients. New England Journal of Medicine2001; 345: 715–724.
7.
SimonsJ.N., LearyT.P., DawsonG.J., Pilot-MatiasT.J., MuerhoffA.S., SchlauderG.G., DesaiS.M., & MushahwarI.K.Isolation of novel virus-like sequences associated with human hepatitis. Nature Medicine1995; 1: 564–569.
8.
PavesiA.Origin and evolution of GBV-C/hepatitis G virus and relationships with ancient human migrations. Journal of Molecular Evolution2001; 53: 104–113.
9.
HalaszR., WeilandO., & SallbergM.GB virus C/hepatitis G virus. Scandanavian Journal of Infectious Diseases2001; 33: 572–580.
10.
TuckerT.J., & SmutsH.E.GBV-C/HGV genotypes: proposed nomenclature for genotypes 1-5. Journal of Medical Virology2000; 62: 82–83.
11.
StosorV., & WolinskyS.GB virus C and mortality from HIV infection. New England Journal of Medicine2001; 345: 761–762.
12.
KleinmanS.Hepatitis G virus biology, epidemiology, and clinical manifestations: Implications for blood safety. Transfusion Medicine Reviews2001; 15: 201–212.
13.
TramontE.C.Treponema pallidum (Syphilis). In Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, vol. 22000; 2474–2490. Edited by MandellG.E., BennettJ.E., & DolinR.Philadelphia: Churchill Livingstone.
14.
BraslowJ.T.The influence of a biological therapy on physicians’ narratives and interrogations: the case of general paralysis of the insane and malaria fever therapy, 1910–1950. Bulletin of the History of Medicine1996; 70: 577–608.
15.
CherninE.The malariatherapy of neurosyphilis. Journal of Parasitology1984; 70: 611–617.
16.
BondH.[Preface to] General Paralysis and its Treatment by Induced Malaria.1929. London: HMS Stationary Office.
17.
WhitrowM.Wagner-Jauregg and fever therapy. Medical History1990; 34: 294–310.
18.
Wagner-JaureggJ.Ueber die Einwirkung fieberhafter Erkrankungen auf Psychosen. Jarbuch de Psychologie und Neurologie1887; 7: 94–131.
19.
Wagner-JaureggJ.The treatment of dementia paralytica by malaria inoculation. Nobel Lecture, 13 December 1927. Vol. 2001. Nobel e-Museum: The Nobel Foundation, 1927.
20.
SartinJ.S., & PerryH.O.From mercury to malaria to penicillin: the history of the treatment of syphilis at the Mayo Clinic: 1916–1955. Journal of the American Academy of Dermatology1995; 32: 255–261.
21.
Anonymous.Editorial. American Journal of Psychiatry1923; 79: 721–723.
22.
AlbertM.R.Fever therapy for general paresis. International Journal of Dermatology1999; 38: 633–637.
23.
O'LearyP.A., BruetschW.L., EbaughF.G., SimpsonW.M., SolomonH.C., WarrenS.L., UsiltonL.J., & SollinsI.V.Malaria and artificial fever in the treatment of paresis. Journal of the American Medical Association1940; 115: 677–681.
24.
OslerW.The Principles and Practice of Medicine.2 edn1895. New York: Appleton.
25.
StolleyP.D.Fever Therapy: Lessons from the History and Efficacy of Malariotherapy. In Fever: Basic Mechanisms and Management, 1997; pp. 331–336. Edited by MackowiakP.A.Philadelphia: Lippincott-Raven.
26.
WernstedtW.Nobel Prize in Physiology or Medicine 1927 Presentation Speech. Nobel Prize in Physiology or Medicine 1927 Presentation Speech. Vol. 2001. Nobel e-Museum: The Nobel Foundation, 1927.
27.
Anonymous.From the Centers for Disease Control. Self-induced malaria associated with malariotherapy for Lyme disease – Texas. Journal of the American Medical Association1991; 266: 2199.
28.
Anonymous.From the Centers for Disease Control. Imported malaria associated with malariotherapy of Lyme disease – New Jersey. Journal of the American Medical Association1991; 265: 317–318.
29.
HeimlichH.J., ChenX.P., XiaoB.Q., LiuS.G., LuY.H., SpletzerE.G., & YaoJ.L.Malariotherapy for HIV patients. Mechanisms of Ageing & Development1997; 93: 79–85.
30.
GreentreeL.B.Malariotherapy and cancer. Medical Hypotheses1981; 7: 43–49.
31.
BowdenT.A.Jr., MansbergerA.R.Jr., & LykinsL.E.Pseudomembraneous enterocolitis: mechanism for restoring floral homeostasis. American Surgeon1981; 47: 178–183.
32.
SchwanA., SjolinS., TrottestamU., & AronssonB.Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces. Scandanavian Journal of Infectious Diseases1984; 16: 211–215.
33.
Lund-TonnesenS., BerstadA., SchreinerA., & MidtvedtT.[Clostridium difficile-associated diarrhea treated with homologous feces]. Tidsskriftet for Den norske Laegeforening1998; 118: 1027–1030.
WattG., KantipongP., JongsakulK., de SouzaM., & BurnoufT.Passive transfer of scrub typhus plasma to patients with AIDS: a descriptive clinical study. QJM2001; 94: 599–607.
36.
SimonsJ.N., Pilot-MatiasT.J., LearyT.P., DawsonG.J., DesaiS.M., SchlauderG.G., MuerhoffA.S., ErkerJ.C., BuijkS.L., ChalmersM.L., Van SantC.L., & MushahwarI.K.Identification of two flavivirus-like genomes in the GB hepatitis agent. Proceedings of the National Academy of Sciences of the USA1995; 92: 3401–3405.
37.
LinnenJ., WagesJ.Jr., Zhang-KeckZ Y., FryK.E., KrawczynskiK.Z., AlterH., KooninE., GallagherM., AlterM., HadziyannisS., KarayiannisP., FungK., NakatsujiY., ShihJ.W., YoungL., PiatakM.Jr., HooverC., FernandezJ., ChenS., ZouJ.C., MorrisT., HyamsK.C., IsmayS., LifsonJ.D., KimJ.P.Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science1996; 271: 505–508.
38.
LearyT.P., MuerhoffA.S., SimonsJ.N., Pilot-MatiasT.J., ErkerJ.C., ChalmersM.L., SchlauderG.G., DawsonG.J., DesaiS.M., & MushahwarI.K.Sequence and genomic organization of GBV-C: a novel member of the flaviviridae associated with human non-A-E hepatitis. Journal of Medical Virology1996; 48: 60–67.
39.
FogedaM., NavasS., MartinJ., CasqueiroM., RodriguezE., ArocenaC., & CarrenoV.In vitro infection of human peripheral blood mononuclear cells by GB virus C/Hepatitis G virus. Journal of Virology1999; 73: 4052–4061.
40.
XiangJ., WunschmannS., SchmidtW., ShaoJ., & StapletonJ.T.Full-length GB virus C (Hepatitis G virus) RNA transcripts are infectious in primary CD4-positive T cells. Journal of Virology2000; 74: 9125–9133.
41.
XiangJ., KlinzmanD., McLindenJ., SchmidtW.N., LaBrecqueD.R., GishR., & StapletonJ.T.Characterization of hepatitis G virus (GB-C virus) particles: evidence for a nucleocapsid and expression of sequences upstream of the E1 protein. Journal of Virology1998; 72: 2738–2744.
42.
XiangJ., DanielsK.J., SollD.R., SchmidtW.N., LabrecqueD.R., & StapletonJ.T.Visualization and characterization of GB virus-C particles: evidence for a nucleocapsid. Journal of Viral Hepatitis1999; 6(Suppl. 1): 16–22.
43.
HalaszR., SallbergM., LundholmS., AnderssonG., LagerB., GlaumannH., & WeilandO.The GB virus C/hepatitis G virus replicates in hepatocytes without causing liver disease in healthy blood donors. Journal of Infectious Diseases2000; 182: 1756–1760.
44.
AgnelloV., AbelG., ElfahalM., KnightG.B., & ZhangQ.X.Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proceedings of the National Academy of Sciences USA1999; 96: 12766–12771.
45.
TheodoreD., & LemonS.M.GB virus C, hepatitis G virus, or human orphan flavivirus. Hepatology1997; 25: 1285–1286.
46.
AlterM.J., GallagherM., MorrisT.T., MoyerL.A., MeeksE.L., KrawczynskiK., KimJ.P., & MargolisH.S.Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection. Sentinel Counties Viral Hepatitis Study Team. New England Journal of Medicine1997; 336: 741–746.
47.
AlterH.J., NakatsujiY., MelpolderJ., WagesJ., WesleyR., ShihJ.W., & KimJ.P.The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease. New England Journal of Medicine1997; 336: 747–754.
48.
MartinP., FabriziF., DixitV., BrezinaM., GerosaS., RussellJ., ConradA., & GitnickG.Epidemiology and natural history of hepatitis G virus infection in chronic hemodialysis patients. American Journal of Nephrology1999; 19: 535–540.
49.
RostaingL., IzopetJ., ArnaudC., CisterneJ.M., AlricL., RumeauJ.L., DuffautM., & DurandD.Long-term impact of superinfection by hepatitis G virus in hepatitis C virus-positive renal transplant patients. Transplantation1999; 67: 556–560.
50.
YuM.L., ChuangW.L., WangL.Y., DaiC.Y., ChiouS.S., SungM.H., ChangC.S., ChenS.C., WangC.S., ChangT.T., & ChangW.Y.Status and natural course of GB virus C/hepatitis G virus infection among high-risk groups and volunteer blood donors in Taiwan. Journal of Gastroenterology and Hepatology2000; 15: 1404–1410.
51.
De FilippiF., LamperticoP., SoffrediniR., RumiM.G., LunghiG., AroldiA., TarantinoA., PonticelliC., & ColomboM.High prevalence, low pathogenicity of hepatitis G virus in kidney transplant recipients. Digestive and Liver Disease2001; 33: 477–479.
52.
StarkK., DoeringC.D., BienzleU., PauliG., HamoudaO., EngelA.M., & SchreierE.Risk and clearance of GB virus C/hepatitis G virus infection in homosexual men: A longitudinal study. Journal of Medical Virology1999; 59: 303–306.
53.
IsaacsonA.H., BhardwajB., QianK., DavisG.L., KatoT., MizokamiM., & LauJ.Y.Hepatitis G virus infection in renal transplant recipients. Journal of Viral Hepatitis1999; 6: 151–160.
54.
EllenriederV., WeidenbachH., FrickhofenN., MichelD., PrummerO., KlattS., BernasO., MertensT., AdlerG., & BeckhK.HCV and HGV in B-cell non-Hodgkin's lymphoma. Journal of Hepatology1998; 28: 34–39.
55.
AlterH.J.G-pers creepers, where'd you get those papers? A reassessment of the literature on the hepatitis G virus. Transfusion1997; 37: 569–572.
56.
MosierD.E., & ChisariF.V.GB virus C and mortality from HIV infection. New England Journal of Medicine2002; 346: 377–379.
57.
TakamatsuJ., ToyodaH., & FukudaY.GB virus C and mortality from HIV infection. New England Journal of Medicine2002; 346: 377–379.
58.
OrensteinW.A., WhartonM., BartK.J., & HinmanA.R.Immunization. In Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, vol. 22000; pp. 3207–3234. Edited by MandellG.E., BennettJ.E., & DolinR.Philadelphia: Churchill Livingstone.
59.
IkedaM., SugiyamaK., MizutaniT., TanakaT., TanakaK., ShimotohnoK., & KatoN.Hepatitis G virus replication in human cultured cells displaying susceptibility to hepatitis C virus infection. Biochemistry Biophysics Research Communications1997; 235: 505–508.
60.
ShimizuY.K., HijikataM., KiyoharaT., KitamuraY., & YoshikuraH.Replication of GB virus C (hepatitis G virus) in interferon-resistant Daudi cells. Journal of Virology1999; 73: 8411–8414.
61.
Anonymous.The global HIV and AIDS epidemic, 2001Morbidity and Mortality Weekly Report2001; 50: 434–439.
